CFM
KYNB

Catalyst Funds Management’s Kyntra Bio KYNB Stock Holding History

Catalyst Funds Management’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-948
Closed -$9.47K – 675
2024
Q3 		$9.47K Hold
948
– – ﹤0.01% 1193
2024
Q2 		$21.1K Buy
+948
New +$29.3K 0.01% 660

Other funds holding KYNB

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Catalyst Funds Management's KYNB Position: Q4 2024 in Review

Catalyst Funds Management sold out of Kyntra Bio (KYNB) in Q4 2024, closing a stake of 948 shares — an estimated $9.47K sold.

Catalyst Funds Management first reported a position in KYNB in Q2 2024 and held it in 2 quarters. The position peaked at $21.1K in Q2 2024. 68 funds tracked by Wall St. Rank hold KYNB as of Q4 2024.

  • Catalyst Funds Management reported no remaining Kyntra Bio position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 948 Kyntra Bio shares in Q4 2024, an estimated $9.47K.
  • Catalyst Funds Management first reported a position in Kyntra Bio in Q2 2024 and held it in 2 quarters.
  • Catalyst Funds Management's Kyntra Bio position peaked at $21.1K in Q2 2024.
  • 68 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.